Mercer Global Advisors
SRPT icon

Mercer Global Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Mercer Global Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$931K Sell
51,799
-26,441
-34% -$500K ﹤0.01% 1797
2026
Q1 		$1.7M Sell
78,240
-17,512
-18% -$339K ﹤0.01% 1267
2025
Q4 		$2.06M Buy
95,752
+74,027
+341% +$1.56M ﹤0.01% 1092
2025
Q3 		$419K Buy
+21,725
New +$387K ﹤0.01% 1869
2025
Q1 		– Sell
-1,897
Closed -$231K – 2250
2024
Q4 		$231K Sell
1,897
-1,228
-39% -$150K ﹤0.01% 1892
2024
Q3 		$382K Sell
3,125
-2,496
-44% -$345K ﹤0.01% 1492
2024
Q2 		$888K Buy
5,621
+1,630
+41% +$209K ﹤0.01% 1020
2024
Q1 		$517K Buy
3,991
+1,643
+70% +$201K ﹤0.01% 1259
2023
Q4 		$226K Buy
2,348
+71
+3% +$6.81K ﹤0.01% 1766
2023
Q3 		$276K Sell
2,277
-93
-4% -$10.5K ﹤0.01% 1582
2023
Q2 		$271K Buy
2,370
+195
+9% +$25.1K ﹤0.01% 1567
2023
Q1 		$300K Buy
+2,175
New +$282K ﹤0.01% 1511

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Mercer Global Advisors's SRPT Position: Q2 2026 in Review

Mercer Global Advisors reduced its Sarepta Therapeutics (SRPT) stake by 34% in Q2 2026, selling an estimated $500K and leaving 51,799 shares worth $931K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Mercer Global Advisors first reported a position in SRPT in Q1 2023 and has held it in 12 quarters since. The position peaked at $2.06M in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Mercer Global Advisors held 51,799 shares of Sarepta Therapeutics worth $931K as of Q2 2026.
  • Mercer Global Advisors sold 26,441 Sarepta Therapeutics shares in Q2 2026, an estimated $500K.
  • Sarepta Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #1797 holding.
  • Mercer Global Advisors first reported a position in Sarepta Therapeutics in Q1 2023 and has held it in 12 quarters since.
  • Mercer Global Advisors's Sarepta Therapeutics position peaked at $2.06M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.